Sarepta Therapeutics Inc Stock Price, News & Analysis

Sarepta Therapeutics (NASDAQ:SRPT) announced on May 28, 2021, that it granted equity awards to six new employees as part of its 2014 Employment Commencement Incentive Plan. The awards include options to purchase 6,295 shares at an exercise price of $75.65 per share and a total of 2,950 restricted stock units (RSUs). The options will vest over four years, while the RSUs will also fully vest by the fourth anniversary of the grant date. This step aligns with Nasdaq Listing Rule 5635(c)(4), emphasizing Sarepta's commitment to attracting talent in precision genetic medicine for rare diseases.

Sarepta Therapeutics (NASDAQ:SRPT) announced positive results from the first 11 participants in Study SRP-9001-103 ENDEAVOR. The study shows robust transduction with mean vector genome copies of 3.87 per nucleus and micro-dystrophin expression levels at 55.4% of normal. Proper localization of micro-dystrophin was confirmed, with 70.5% dystrophin-positive fibers. The safety profile remains consistent with previous studies, with no new safety signals. These findings support the potential of SRP-9001 as a transformative therapy for Duchenne muscular dystrophy, leading to plans for an FDA meeting to start a registrational study.

Sarepta Therapeutics (NASDAQ:SRPT) will host a conference call on May 18, 2021, at 8:30 am ET, to share results from the SRP-9001-103 clinical trial, also known as ENDEAVOR. This trial evaluates SRP-9001 (rAAVrh74.MHCK7.micro-dystrophin) for treating Duchenne muscular dystrophy. It marks the first use of commercially representative material in a clinical setting. The event will be webcast live and archived for a year.

Sarepta Therapeutics (NASDAQ:SRPT) reported first-quarter 2021 net product sales of $124.9 million, a 24% increase from the previous year. The company launched its third RNA therapy for Duchenne, AMONDYS 45™, shortly after FDA approval. Significant advancements in pipeline development were noted, particularly with SRP-5051, which showed an 18x increase in exon skipping compared to a standard treatment. However, the company reported a GAAP net loss of $167.3 million, reflecting increased R&D expenses of $195.1 million. Cash reserves decreased from $1.9 billion to $1.7 billion.

Sarepta Therapeutics (NASDAQ:SRPT) announced its participation in two upcoming virtual investor conferences. Management will engage in fireside chats at the BofA Securities Virtual Healthcare Conference on May 11, 2021, at 2:00 p.m. E.T., and the RBC 2021 Global Healthcare Conference on May 18, 2021, at 2:30 p.m. E.T. Both presentations will be webcast live and archived on Sarepta’s website for 90 days. Sarepta is dedicated to precision genetic medicine for rare diseases, holding a leadership position in Duchenne muscular dystrophy and limb-girdle muscular dystrophies.

Sarepta Therapeutics (NASDAQ:SRPT) announced positive results from the Phase 2 MOMENTUM study of its next-generation treatment, SRP-5051, for Duchenne muscular dystrophy. The 30 mg/kg dose revealed a mean exon skipping of 10.79% and dystrophin expression of 6.55% after 12 weeks, significantly outperforming the eteplirsen comparison group. The company anticipates achieving over 10% dystrophin levels with ongoing monthly dosing. Despite manageable hypomagnesemia in some patients, Sarepta is optimistic about advancing toward regulatory discussions for accelerated approval.

Sarepta Therapeutics (NASDAQ:SRPT) announced the granting of equity awards to four new employees on April 30, 2021, under its 2014 Employment Commencement Incentive Plan. The total awards included options for 8,615 shares and 3,275 restricted stock units (RSUs). The options have an exercise price of $70.84 per share, matching the closing stock price on the grant date. Vesting for options and RSUs is set over four years, contingent on continued employment.

Sarepta Therapeutics (NASDAQ:SRPT) will host a webcast and conference call on May 3, 2021, at 8:30 am ET to present results from the 30 mg/kg arm of the MOMENTUM study. This clinical trial evaluates SRP-5051, the company's investigational treatment for Duchenne muscular dystrophy (DMD). SRP-5051 utilizes Sarepta's innovative PPMO platform to enhance drug delivery to muscle tissue. The live presentation will be accessible via Sarepta's investor relations website, with archived slides available for one year.

Sarepta Therapeutics (NASDAQ:SRPT) will announce its first quarter 2021 financial results after market close on May 5, 2021. A conference call to discuss these results and provide a corporate update will follow at 4:30 p.m. E.T. Interested parties can access the call via domestic and international numbers provided in the release, with a live webcast available on Sarepta's website. Sarepta focuses on precision genetic medicine for rare diseases, notably Duchenne muscular dystrophy, and has over 40 development programs in its pipeline.